A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors
Latest Information Update: 23 Feb 2023
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2022 Planned End Date changed from 30 Sep 2022 to 31 Dec 2024.
- 18 Jan 2022 Planned primary completion date changed from 30 Sep 2021 to 31 Dec 2024.